Shionogi, GlaxoSmithKline To Start Phase-3 Study For HIV Drug

21st Jul 2010 10:47

TOKYO (Dow Jones)--Shionogi & Co. (4507.TO) said Wednesday it and GlaxoSmithKline PLC (GSK) will start a phase-3 clinical study on their HIV infection treatment S/GSK1349572 following favorable results from second stage phase-2 trials. S/GSK1349572 is for HIV-infected patients who have never been treated with anti-HIV drugs or haven't responded well to Merck & Co.'s (MRK) Isentress, which belongs to the same treatment class. -By Kazuhiro Shimamura, Dow Jones Newswires; 813-6269-2790; [email protected] (END) Dow Jones Newswires July 21, 2010 05:47 ET (09:47 GMT)

Top Risers

Share	Price	Change
Huddled Group (HUD)	0.85	24.14%
Eurasia Mining (EUA)	2.80	19.15%
Genincode (GENI)	0.725	16%
Medpal AI (MPAL)	5.25	14.13%
Light Science Technologies (LST)	0.875	12.9%

Top Fallers

Share	Price	Change
Catenai Plc (CTAI)	0.0575	-39.47%
Petra Diamonds (PDL)	2.60	-26.14%
Focus Xplore (FOX)	0.019	-22.45%
Litigation Cap. (LIT)	0.301	-20.12%
Abrdn Property (API)	1.52	-15.56%

Top By Volume

Share	Price	Volume
Ethernity Net (ENET)	0.0019	1,922,336,250
Forgent (FORG)	0.0115	591,087,829
Premier African Minerals (PREM)	0.0044	313,776,718
Focus Xplore (FOX)	0.019	253,421,870
Bezant Resources PLC (BZT)	0.11	246,929,868

All prices are delayed by at least 15 minutes. Share Compare cannot be held responsible for the accuracy of share prices shown on this website, and investors should be aware that share prices can go down as well as up. Share Compare does not offer advice, and is not regulated by the Financial Conduct Authority.